Inhibitory effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on repiration and growth of adenocarcinoma TA3 and its multiresistant variant TA3MTX-R

In Vivo

Volumn 22, Issue 3, 2008, Pages 353-362

  Plaza, Claudio ^a   Pavani, Mario ^a   Faundez, Mario ^a   Maya, Juan Diego ^a   Morello, Antonio ^a   Becker, Maria Inés ^c   De Ioannes, Alfredo ^c   Cumsille, Miguel Angel ^b   Ferreira, Jorge ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c NONE   (Chile)

Author keywords

ATP level; Cytotoxicity; Inhibition; Nordihydroguaiaretic acid derivative; Respiration; Tumor cell growth

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CISPLATIN; DOXORUBICIN; DUROQUINOL; FLUOROURACIL; GLUTAMIC ACID; MALIC ACID; MITOXANTRONE; NORDIHYDROGUAIARETIC ACID; TETRACETYLATED NORDIHYDROGUAIARETIC ACID DERIVATIVE; UBIQUINONE; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL METABOLISM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ELECTRON TRANSPORT; LIVER METABOLISM; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OXYGEN CONSUMPTION;

EID: 45949100666     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Siddique YH, Beg T and Afzal M: Protective effect of nordihydroguaiaretic acid (NDGA) against norgestrel induced genotoxic damage. Toxicol In Vitro 20: 227-233, 2006.
2. Floriano-Sánchez E, Villanueva C, Medina-Campos ON, Rocha D, Sánchez-González DJ, Cárdenas-Rodríguez N and Pedraza-Chaverrí J: Nordihydroguaiaretic acid is a potent in vitro scavenger of peroxynitrite, singlet oxygen, hydroxyl radical, superoxide anion and hypochlorous acid and prevents in vivo ozone-induced tyrosine nitration in lungs. Free Radic Res 40: 523-533, 2006.
3. Miller RA, Harrison DE, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR and Strong R: An Aging Interventions Testing Program: study design and interim report. Aging Cell 6: 565-575, 2007.
4. Sahu SC, Ruggles DI and O'Donnell MW: Prooxidant activity and toxicity of nordihydroguaiaretic, acid in clone-9 rat hepatocyte cultures. Food Chem Toxicol 44: 1751-1757, 2006.
5. Goodman T, Grice HC, Becking GC and Salem FA: A cystic nephropathy induced by nordihydroguaiaretic acid in the rat. Light and electron microscopic investigations. Lab Invest 23: 93-107, 1970.
6. Lambert JD, Zhao D, Meyers RO, Kuester RK, Timmermann BN and Dorr RT: Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. Toxicon 40: 1701-1708, 2002.
7. Ansar S, Iqbal M and Athar M: Nordihydroguairetic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity, and renal tumour promotion, in mice. Carcinogenesis 20: 599-606, 1999.
8. Hagmann W: Lipoxygenase in human tumor cells. Pathol Oncol Res 3: 83-88, 1997.
9. Timár J, Rásó E, Döme B, Li L, Grignon D, Nie D, Honn KV and Hagmann W: Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 87: 37-43 2000.
10. Shureiqi I and Lippman SM: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 61: 6307-6312, 2001.
11. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J and Goldfine ID: Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 94: 37-46 2005.
12. Deshpande VS and Kehrer JP: Oxidative stress-driven mechanisms of nordihydroguaiaretic acid-induced apoptosis in FL5.12 cells. Toxicol Appl Pharmacol 214: 230-236 2006.
13. Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, Wakada M, Mizutani Y, Miki T, Nishikawa A and Sakai T: Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci 98: 1417-1423, 2007.
14. Tong WG, Ding XZ, Witt RC and Adrian TE: Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1: 929-935, 2002.
15. Burk D and Woods M: Hydrogen peroxide, catalase, glutathione peroxidase, quinones, nordihydroguaiaretic acid, and phosphopyridine nucleotides in relation to X-Ray action on cancer cells. Radiat Res Suppl 3: 212-246, 1963.
16. Peng Q, Moan J and Cheng LS: The effect of glucose administration on the uptake of photofrin II in a human tumor xenograft. Cancer Lett 58: 29-35, 1991.
17. Fones E, Amigo H, Gallegos K, Guerrero A and Ferreira J: t-Butyl-4-hydroxyanisole as an inhibitor of tumor cell respiration. Biochern Pharmacol 38: 3443-3451, 1989.
18. Pavani M, Fones E, Oksenberg D, Garcia M, Hernández C, Cordano G, Muñoz S, Mancilla J, Guerrero A and Ferreira J: Inhibition of tumoral cell respiration and growth by nordihydro-guaiaretic acid. Biochem Pharmacol 48: 1935-1942, 1994.
19. Bhuvaneswaran C and Dakshinamurti K: Inhibition of electron and energy transfer in rat liver mitochondria by nordihydroguaiaretic acid. Biochemistry 11: 85-91, 1972.
20. Shi L and Pardini RS: Effect of NDGA on beef heart mitochondria and EMT6 mouse mammary carcinoma cells. Res Commun Mol Path Pharmacol 90: 235-254, 1995.
21. Billinsky JL, Marcoux MR and Krol ES: Oxidation of the lignan nordihydroguaiaretic acid. Chem Res Toxicol 20: 1352-1358, 2007.
22. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ and Capaldi RA: Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 64: 985-993, 2004.
23. Penta JS, Johnson FM, Wachsman JT and Copeland WC: Mitochondrial DNA in human malignancy. Mutat Res 488: 119-133, 2001.
24. Cordano G, Pezoa J, Muñoz S, Rivera E, Medina J, Náñez-Vergara LJ, Pavani M, Guerrero A and Ferreira J: Inhibitory effect of vanillin-like compounds on respiration and growth of adenocarcinoma TA3 and its multiresistant variant TA3-MTXR. Eur J Pharm Sci 16: 255-263, 2002.
25. Frey C, Pavani M, Cordano G, Muñoz S, Rivera E, Medina J, Morello A, Maya JD and Ferreira J: Comparative cytotoxicity of alkyl gallates on mouse tumor cells lines and isolates rat hepatocytes. Comp Biochem Physiol A Mol Integr Physiol 146: 520-527, 2007.
26. Boveris A, Oshino R, Erecinska M and Chance B: Reduction of mitochondrial components by durohydroquinone. Biochim Biophys Acta 245: 1-16, 1971.
27. Moreadith RW and Fiskum G: Isolation of mitochondria from ascites tumor cells permeabilized with digitonin. Anal Biochem 137: 360-367, 1984.
28. Ferreira J and Gil L: Nutritional effects on mitochondrial bioenergetics. Alterations in oxidative phosphorylation by rat liver mitochondrial. Biochem J 218: 61-67, 1984.
29. Lowry OH, Rosenbrough NJ, Farr AL and Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
30. Dean M, Fojo T and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
31. Pedersen P L, Mathupala S, Rempel A, Geschwind JF and Ko Y: Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555: 14-20, 2002.
32. Hashimoto M and Wilson JE: Membrane potential-dependent conformational changes in mitochondrially bound hexokinase of brain. Arch Biochem Biophys 384: 163-173, 2000.
33. Azoulay-Zohar H, Israelson A, Abu-Hamad S and Shoshan-Barmatz V: In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 377: 347-355, 2004.
34. Pedersen P: Tumor mitochondria and bioenergetics of cancer cells. Prog Exp Tumor Res 22: 190-274, 1978.
35. Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC and Huang RC: Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or pachtaxel. Cancer Chemother Pharmacol 58: 640-653, 2006.
36. Huang RC, Chang CC and Mold D: Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin Oncol 33: 479-485, 2006.
37. Mak DH, Schober WD, Chen W, Heller J, Andreeff M and Carter BZ: Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma 48: 774-785, 2007.
38. Lopez RA, Goodman AB, Rhodes M, Blomberg JA and Heller J: The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Anticancer Drugs 18: 933-939, 2007.
39. Allen KL, Tschantz DR, Awad KS, Lynch WP and DeLucia AL: A plant lignan, 3′-O-medlyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells. Mol Carcinog 46: 564-575, 2007.